Disease Info Card

Tyrosinase-negative Oculocutaneous Albinism

Information about Tyrosinase-negative Oculocutaneous Albinism: characteristics, related genes and pathways, plus antibodies you can use for research. This page is being enriched constantly, if you see some information you would like this page to include please send your suggestions to us.

Overview of Tyrosinase-negative Oculocutaneous Albinism

Most recent studies have shown that Tyrosinase-negative Oculocutaneous Albinism shares some biological mechanisms with albinism, albinism-ocular, albinism-oculocutaneous, congenital-nystagmus, dysplasia, esotropia, fetal-diseases, hereditary-diseases, hypopigmentation-disorder, hypoplasia, malignant-paraganglionic-neoplasm, melanoma, melanoma-amelanotic, mutation-out-of-frame, neoplasms, nystagmus, ocular-albinism-type-i, photophobia, piebaldism, skin-neoplasms.

Among the many pathways, these few ones have gauged particular interests from scientists studying Tyrosinase-negative Oculocutaneous Albinism, and have been seen in publications frequently: Cellular Localization, Developmental Process, Excretion, Hypersensitivity, Localization, Neuroblast Division, Pathogenesis, Pigment Accumulation, Pigmentation, Protein Folding, Response To Uv, Translation

Quite a number of genes have been found to play important roles in Tyrosinase-negative Oculocutaneous Albinism, such as AGA, ARSA, CANX, CTSC, EGF, GLS2, GPR143, GPR151, HBB, HPS1, LAMP1, MITF, MTSS1, OCA2, PAX3, SLC45A2, TH, TYR, TYRP1. See what Boster has to offer for the research of these genes by clicking the gene name links below and view a more detailed info card/product listing for that gene.

In a later update, we will include information such as current drugs and therapy solutions as well as on-going and past clinical trials for this disease. Plesae stay updated.